Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5‐year update of the<scp>NURTURE</scp>study
Thomas O. Crawford(Johns Hopkins University), Russell L. Chin(Biogen (United States)), Zdenek Berger(Moderna Therapeutics (United States)), Angela D. Paradis(Biogen (United States)), Janbernd Kirschner(University of Freiburg), Monique M. Ryan(Royal Children's Hospital), Nancy L. Kuntz(Lurie Children's Hospital), Valeria Sansone(University of Milan), Francy Shu(University of California, Los Angeles), Yuh‐Jyh Jong(National Yang Ming Chiao Tung University), Wuh‐Liang Hwu(MRC Epidemiology Unit), Tawfeg Ben‐Omran(Qatar Airways (Qatar)), Darryl C. De Vivo(Columbia University Irving Medical Center), Astrid Pechmann(University of Freiburg), Tiffany R. Lago(Biogen (United States)), Enrico Bertini(Bambino Gesù Children's Hospital), Russell J. Butterfield(University of Utah), Aledie Navas-Nazario(Nemours Children's Clinic), Kathryn J. Swoboda(Massachusetts General Hospital), Stephanie Raynaud(Biogen (United States)), Richard S. Finkel(St. Jude Children's Research Hospital), Haluk Topaloğlu(Yeditepe University), Julie Parsons, Richard Foster(Massachusetts Institute of Technology), Cong Zhu(Biogen (United States))
Cited by 117
Related Papers
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
|Nature|2006|2.1k
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k